270 related articles for article (PubMed ID: 29922288)
1. Translating Observations From Leishmanization Into Non-Living Vaccines: The Potential of Dendritic Cell-Based Vaccination Strategies Against
Seyed N; Peters NC; Rafati S
Front Immunol; 2018; 9():1227. PubMed ID: 29922288
[TBL] [Abstract][Full Text] [Related]
2. Vector transmission of leishmania abrogates vaccine-induced protective immunity.
Peters NC; Kimblin N; Secundino N; Kamhawi S; Lawyer P; Sacks DL
PLoS Pathog; 2009 Jun; 5(6):e1000484. PubMed ID: 19543375
[TBL] [Abstract][Full Text] [Related]
3. Enhanced protective efficacy of nonpathogenic recombinant leishmania tarentolae expressing cysteine proteinases combined with a sand fly salivary antigen.
Zahedifard F; Gholami E; Taheri T; Taslimi Y; Doustdari F; Seyed N; Torkashvand F; Meneses C; Papadopoulou B; Kamhawi S; Valenzuela JG; Rafati S
PLoS Negl Trop Dis; 2014 Mar; 8(3):e2751. PubMed ID: 24675711
[TBL] [Abstract][Full Text] [Related]
4. Th1 concomitant immune response mediated by IFN-γ protects against sand fly delivered Leishmania infection: Implications for vaccine design.
Seyed N; Rafati S
Cytokine; 2021 Nov; 147():155247. PubMed ID: 32873468
[TBL] [Abstract][Full Text] [Related]
5. Induction of protective CD4+ T cell-mediated immunity by a Leishmania peptide delivered in recombinant influenza viruses.
Kedzierska K; Curtis JM; Valkenburg SA; Hatton LA; Kiu H; Doherty PC; Kedzierski L
PLoS One; 2012; 7(3):e33161. PubMed ID: 22470440
[TBL] [Abstract][Full Text] [Related]
6. Differences in immune responses against Leishmania induced by infection and by immunization with killed parasite antigen: implications for vaccine discovery.
Mendonça SC
Parasit Vectors; 2016 Sep; 9(1):492. PubMed ID: 27600664
[TBL] [Abstract][Full Text] [Related]
7. KSAC, a defined Leishmania antigen, plus adjuvant protects against the virulence of L. major transmitted by its natural vector Phlebotomus duboscqi.
Gomes R; Teixeira C; Oliveira F; Lawyer PG; Elnaiem DE; Meneses C; Goto Y; Bhatia A; Howard RF; Reed SG; Valenzuela JG; Kamhawi S
PLoS Negl Trop Dis; 2012; 6(4):e1610. PubMed ID: 22509423
[TBL] [Abstract][Full Text] [Related]
8. New Vaccine Formulations Containing a Modified Version of the Amastigote 2 Antigen and the Non-Virulent
Almeida APMM; Machado LFM; Doro D; Nascimento FC; Damasceno L; Gazzinelli RT; Fernandes AP; Junqueira C
Front Immunol; 2018; 9():465. PubMed ID: 29599776
[TBL] [Abstract][Full Text] [Related]
9. Cutaneous leishmaniasis: progress towards a vaccine.
Launois P; Tacchini-Cottier F; Kieny MP
Expert Rev Vaccines; 2008 Oct; 7(8):1277-87. PubMed ID: 18844599
[TBL] [Abstract][Full Text] [Related]
10.
Ismail N; Karmakar S; Bhattacharya P; Sepahpour T; Takeda K; Hamano S; Matlashewski G; Satoskar AR; Gannavaram S; Dey R; Nakhasi HL
Front Immunol; 2022; 13():864031. PubMed ID: 35419001
[TBL] [Abstract][Full Text] [Related]
11. Not All Antigens Are Created Equally: Progress, Challenges, and Lessons Associated with Developing a Vaccine for Leishmaniasis.
Duthie MS; Reed SG
Clin Vaccine Immunol; 2017 Jul; 24(7):. PubMed ID: 28515135
[TBL] [Abstract][Full Text] [Related]
12. Determinants of Innate Immunity in Visceral Leishmaniasis and Their Implication in Vaccine Development.
Volpedo G; Pacheco-Fernandez T; Bhattacharya P; Oljuskin T; Dey R; Gannavaram S; Satoskar AR; Nakhasi HL
Front Immunol; 2021; 12():748325. PubMed ID: 34712235
[TBL] [Abstract][Full Text] [Related]
13. Overview of dendritic cell-based vaccine development for leishmaniasis.
Bagirova M; Allahverdiyev AM; Abamor ES; Ullah I; Cosar G; Aydogdu M; Senturk H; Ergenoglu B
Parasite Immunol; 2016 Nov; 38(11):651-662. PubMed ID: 27591404
[TBL] [Abstract][Full Text] [Related]
14. Progress towards a Leishmania vaccine.
Tabbara KS
Saudi Med J; 2006 Jul; 27(7):942-50. PubMed ID: 16830009
[TBL] [Abstract][Full Text] [Related]
15. Induction of protective cellular immune responses against experimental visceral leishmaniasis mediated by dendritic cells pulsed with the N-terminal domain of Leishmania infantum elongation factor-2 and CpG oligodeoxynucleotides.
Agallou M; Pantazi E; Tsiftsaki E; Toubanaki DK; Gaitanaki C; Smirlis D; Karagouni E
Mol Immunol; 2018 Nov; 103():7-20. PubMed ID: 30173073
[TBL] [Abstract][Full Text] [Related]
16. Engineering a vector-based pan-Leishmania vaccine for humans: proof of principle.
Cecílio P; Oristian J; Meneses C; Serafim TD; Valenzuela JG; Cordeiro da Silva A; Oliveira F
Sci Rep; 2020 Oct; 10(1):18653. PubMed ID: 33122717
[TBL] [Abstract][Full Text] [Related]
17. TLR1/2 activation during heterologous prime-boost vaccination (DNA-MVA) enhances CD8+ T Cell responses providing protection against Leishmania (Viannia).
Jayakumar A; Castilho TM; Park E; Goldsmith-Pestana K; Blackwell JM; McMahon-Pratt D
PLoS Negl Trop Dis; 2011 Jun; 5(6):e1204. PubMed ID: 21695103
[TBL] [Abstract][Full Text] [Related]
18. Canine Leishmania vaccines: still a long way to go.
Gradoni L
Vet Parasitol; 2015 Feb; 208(1-2):94-100. PubMed ID: 25620293
[TBL] [Abstract][Full Text] [Related]
19. Pam3CSK4 adjuvant given intranasally boosts anti-Leishmania immunogenicity but not protective immune responses conferred by LaAg vaccine against visceral leishmaniasis.
Salgado CL; Dias EL; Stringari LL; Covre LP; Dietze R; Lima Pereira FE; de Matos Guedes HL; Rossi-Bergmann B; Gomes DCO
Microbes Infect; 2019; 21(7):328-335. PubMed ID: 30817996
[TBL] [Abstract][Full Text] [Related]
20. Leishmania tarentolae secreting the sand fly salivary antigen PpSP15 confers protection against Leishmania major infection in a susceptible BALB/c mice model.
Katebi A; Gholami E; Taheri T; Zahedifard F; Habibzadeh S; Taslimi Y; Shokri F; Papadopoulou B; Kamhawi S; Valenzuela JG; Rafati S
Mol Immunol; 2015 Oct; 67(2 Pt B):501-11. PubMed ID: 26298575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
